Northwest Biotherapeutics, Inc.
NWBO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.21 | 0.30 | 0.05 | -0.03 |
| FCF Yield | -17.30% | -7.23% | -6.99% | -7.25% |
| EV / EBITDA | -5.44 | -15.05 | -8.38 | 3.44 |
| Quality | ||||
| ROIC | 972.34% | -1,606.60% | 85.65% | 61.47% |
| Gross Margin | 100.00% | -1,335.30% | 8.02% | -1,920.70% |
| Cash Conversion Ratio | 0.68 | 0.86 | 0.50 | -0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.36% | 24.34% | 9.24% | -25.29% |
| Free Cash Flow Growth | -1.68% | -2.51% | -25.64% | -14.50% |
| Safety | ||||
| Net Debt / EBITDA | -0.89 | -0.78 | -0.20 | 0.12 |
| Interest Coverage | -8.56 | -10.59 | -11.07 | -10.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -181.49 | -4,159.77 | -196.75 |